Literature DB >> 18299905

Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity.

F Cafini1, L Aguilar, L Alou, M J Giménez, D Sevillano, M Torrico, N González, J J Granizo, J E Martín-Herrero, J Prieto.   

Abstract

This study explores the killing kinetics within 12 h of four oral third-generation cephalosporins against ten Streptococcus pneumoniae strains exhibiting cefotaxime minimum inhibitory concentrations (MICs) from 0.03 to 2 microg/ml. Killing curves were performed with concentrations achievable in serum after standard doses (0.015-4 microg/ml). Reductions of 90% were achieved with all compounds at serum-achievable concentrations for strains exhibiting cefotaxime MIC < or = 0.5 microg/ml. Against strains with cefotaxime MIC > or = 1 microg/ml, only cefditoren reached a 90% reduction with concentrations of 0.5-1 microg/ml doses. At 4 microg/ml, cefditoren and cefotaxime reached 99.9% reduction in seven of the ten strains studied. At serum-achievable concentrations, cefdinir and cefixime were not bactericidal against strains exhibiting cefotaxime MIC > or = 0.25 microg/ml and > or = 0.5 microg/ml, respectively. Cefditoren showed the best killing kinetic profiles and this observation may be important when choosing an oral third-generation cephalosporin as initial or sequential therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18299905     DOI: 10.1007/s10096-008-0493-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers.

Authors:  J J Granizo; B Sádaba; J Honorato; M J Gimenez; D Sevillano; L Aguilar; P Coronel
Journal:  Int J Antimicrob Agents       Date:  2008-01-04       Impact factor: 5.283

Review 2.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

3.  Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain.

Authors:  Emilio Pérez-Trallero; Celia García-de-la-Fuente; César García-Rey; Fernando Baquero; Lorenzo Aguilar; Rafael Dal-Ré; Juan García-de-Lomas
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 4.  Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.

Authors:  Keri Wellington; Monique P Curran
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae.

Authors:  D Sevillano; M J Giménez; L Alou; L Aguilar; F Cafini; M Torrico; N González; O Echeverría; P Coronel; J Prieto
Journal:  J Antimicrob Chemother       Date:  2007-05-04       Impact factor: 5.790

6.  Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae.

Authors:  A Fenoll; M J Giménez; O Robledo; L Aguilar; D Tarragó; J J Granizo; J E Martín-Herrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-18       Impact factor: 3.267

Review 7.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

8.  Antimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae.

Authors:  E Pérez-Trallero; J M Marimón; M Ercibengoa; M J Giménez; P Coronel; L Aguilar
Journal:  Clin Microbiol Infect       Date:  2007-07-06       Impact factor: 8.067

  8 in total
  6 in total

1.  Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.

Authors:  Wanatpreeya Phongsamart; Somporn Srifeungfung; Tanittha Chatsuwan; Pongpun Nunthapisud; Vipa Treerauthaweeraphong; Pimpha Rungnobhakhun; Sirintip Sricharoenchai; Kulkanya Chokephaibulkit
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.

Authors:  Lesley McGee; Donald Biek; Yigong Ge; Magderie Klugman; Mignon du Plessis; Anthony M Smith; Bernard Beall; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

Review 3.  Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

Authors:  María-José Giménez; Lorenzo Aguilar; Juan José Granizo
Journal:  Multidiscip Respir Med       Date:  2018-11-02

4.  The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing.

Authors:  Xuqiao Hu; Zhenru Zhou; Fei Li; Yang Xiao; Zhaoyang Wang; Jinfeng Xu; Fajin Dong; Hairong Zheng; Rongmin Yu
Journal:  Heliyon       Date:  2021-03-01

Review 5.  [Current microbiological aspects of community respiratory infection beyond COVID-19].

Authors:  R Cantón
Journal:  Rev Esp Quimioter       Date:  2021-03-22       Impact factor: 1.553

Review 6.  [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].

Authors:  R Menéndez; R Cantón; A García-Caballero; J Barberán
Journal:  Rev Esp Quimioter       Date:  2019-12-04       Impact factor: 1.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.